BRIEF published on 11/04/2024 at 11:51, 1 year 8 months ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 1 year 8 months ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 1 year 9 months ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
PRESS RELEASE published on 10/11/2024 at 17:45, 1 year 9 months ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 2 years ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 07/09/2024 at 20:45, 2 years ago Inside Information / News release on accounts, results Acticor Biotech publishes its 2023 annual results, financial highlights, and financing outlook. Annual General Meeting scheduled for September 13, 2024 Annual General Meeting Financial Highlights 2023 Annual Results ACTICOR BIOTECH Financing Outlook
BRIEF published on 05/15/2024 at 11:20, 2 years 2 months ago Results of the ACTISAVE study and future perspectives of ACTICOR BIOTECH Stroke Treatment ACTICOR BIOTECH Glenzocimab ESOC 2024 ACTISAVE Study
PRESS RELEASE published on 05/15/2024 at 11:15, 2 years 2 months ago Inside Information / Other news releases ACTICOR BIOTECH presents main results of phase 2/3 ACTISAVE study on stroke treatment at ESOC 2024, targeting specific subgroups for potential benefits Stroke Treatment ACTICOR BIOTECH ESOC 2024 ACTISAVE Study Patient Subgroups
Published on 07/21/2026 at 17:05, 1 hour 26 minutes ago Caldwell Appoints Steven Price Co-Leader of Life Sciences & Healthcare Practice
Published on 07/21/2026 at 15:00, 3 hours 31 minutes ago Four Nines Gold Begins Maiden Drill Program at Hayden Hill
Published on 07/21/2026 at 15:00, 3 hours 31 minutes ago BlackBerry SecuSUITE Secures Renewed NIAP Common Criteria Certification, Reinforcing Leadership in Sovereign Government-Grade Secure Communications
Published on 07/21/2026 at 14:55, 3 hours 36 minutes ago Vulcan Minerals Inc. - Drilling Completed at Carbonear Zinc-Lead SEDEX Project in Newfoundland
Published on 07/21/2026 at 14:30, 4 hours 1 minute ago Sarama Completes Sale of its West Australian Gold Assets
Published on 07/21/2026 at 18:15, 15 minutes ago EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 40 minutes ago The New Measure of an EV Isn't Range, It's Peace of Mind
Published on 07/21/2026 at 17:40, 50 minutes ago EQS-Adhoc: Airbus to present new mid-term outlook, strengthen commitment to profitable growth and shareholder returns during investor update
Published on 07/21/2026 at 17:37, 53 minutes ago EQS-Adhoc: Branicks Group AG updates the timetable for the publication of its 2025 annual and consolidated financial statements in light of ongoing restructuring negotiations
Published on 07/20/2026 at 18:20, 1 day ago Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day ago Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:40, 1 day ago Mersen selected to supply Ford and Leapmotor with fuses for electric vehicles
